Abbott Laboratories (NYSE:ABT) is scheduled to announce Q3 earnings results on Wednesday, October 15th, before market open.
The consensus EPS Estimate is $1.30 (+7.4% Y/Y) and the consensus Revenue Estimate is $11.4B (+7.1% Y/Y).
Over the last 2 years, ABT has beaten EPS estimates 88% of the time and has beaten revenue estimates 75% of the time.
Over the last 3 months, EPS estimates have seen 2 upward revisions and 20 downward. Revenue estimates have seen 16 upward revisions and 7 downward.
Leerink Partners analysts said they are “somewhat cautious” on Abbott’s Q3 EPS, citing “unfavorable shifts in FX” since the last quarterly results, mounting localization pressures in China, and product launch uncertainties around the ongoing government shutdown.
Key themes to keep an eye on would include commentaries on the impact of shifting FX, the latest tariffs and other macro headwinds on sales, and the management appetite for M&A.
